- 1 Comparison of the performance of two targeted metagenomic virus capture probe-based methods
- 2 using synthetic viral sequences and clinical samples
- 3
- 4 Kees Mourik^{1*}, Igor Sidorov¹, Ellen C. Carbo¹, David van der Meer², Arnoud Boot², Aloysius C. M. Kroes¹,
- 5 Eric C.J. Claas¹, Stefan A. Boers¹, Jutte J.C. de Vries^{1*}

¹ Department of Medical Microbiology, Leiden University Center for Infectious Diseases, Leiden

- 7 University Medical Center, Leiden, the Netherlands
- 8 ² GenomeScan B.V., Leiden, the Netherlands
- 9 *Corresponding authors
- 10
- 11 Abstract

12 Viral enrichment by probe hybridization has been reported to significantly increase the sensitivity of13 viral metagenomics.

14 This study compares the analytical performance of two targeted metagenomic virus capture probe-

15 based methods: i) SeqCap EZ HyperCap by Roche (ViroCap) and ii) Twist Comprehensive Viral Research

- 16 Panel workflow, for diagnostic use. Sensitivity, specificity, limit of detection, and effect of human
- 17 background DNA were analysed, using synthetic viral sequences, clinical and reference samples with
- 18 known viral loads.

Sensitivity and specificity were 95% and higher for both methods. Combining thresholds for viral sequence read counts and genome coverage (respectively 500 reads per million and 10% coverage) resulted in optimal prediction of true positive results. Limits of detection were approximately 50-500 copies/ml for both methods. Increasing proportions of spike-in cell free human background sequences did not negatively affect viral detection.

These data show analytical performances in ranges applicable to clinical samples, for both probe hybridization metagenomic approaches. This study supports further steps towards more widespread use of viral metagenomics for pathogen detection, in clinical and surveillance settings using low biomass samples.

28

29 Keywords: viral metagenomics, capture probes, targeted metagenomics, viral diagnostics NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

30 Introduction

31 Viral metagenomics has been gradually applied for broad-spectrum pathogen detection of infectious diseases¹⁻⁵, surveillance of emerging diseases^{3,6-8}, and pathogen discovery^{9,10}. Though metagenomic 32 approaches have been practiced for decades in the field of marine environments and the human 33 microbiome, this approach is nowadays changing how physicians diagnose infectious diseases². 34 Whereas amplicon based metagenomics has been successfully adopted for bacterial diagnostics, no 35 36 amplicon based pan-viral approach is available and therefore viral metagenomics has not yet been widely deployed as diagnostic tool in clinical laboratories¹. One of the main challenges for application 37 38 in clinical settings is the low level of viral genomes in the presence of high levels of host material in 39 patient samples. Several methods for depletion of host sequences and enrichment of viral sequences 40 have been studied with varying success rates¹¹. For example, depletion of host cells prior to extraction of nucleic acids (NA) has been reported to be not advantageous in clinical samples as also intracellular 41 42 viral particles or NA will be removed^{11,12}. In contrast, viral enrichment by probe hybridization methods 43 has been reported to significantly increase sensitivity in various sample types^{1,13-19}, up to the level required for accurate detection of low frequency virus variants²⁰. 44

45 Previously, the performance of a hybridization capture probe panel targeting vertebrate viruses in cerebrospinal fluids from patients with meningo-encephalitis has been analysed²¹. Viral target 46 47 sequence read counts increased 100-10.000 fold compared to unenriched metagenomic sequencing, 48 and sensitivity by enrichment was comparable with polymerase chain reaction (PCR)²¹. Moreover, these earlier data showed that this hybridisation panel of approximately two million capture probes 49 50 designed in 2015 was suited for the detection of novel coronaviruses by reactivity with other vertebrate betacoronavirus probes¹⁰. During the past years, this specific hybridisation panel 51 distributed by Roche has been adopted in a broad range of different clinical^{15,22-29} and zoonotic 52 53 settings^{22,29,30}. Recently, Twist Bioscience has released a new hybridisation panel containing 54 approximately one million size capture probes targeting human and animal viruses. Reports 55 comparing the performance of viral metagenomic hybridisation panels are lacking.

Here, we compare the analytical performance of two targeted metagenomic virus capture probebased methods: i) SeqCap EZ HyperCap by Roche (ViroCap) and ii) Twist Comprehensive Viral Research
Panel workflow, for clinical diagnostic use. Sensitivity, specificity, and limit of detection were analysed
using synthetic viral sequences, clinical and reference samples with known viral loads.

61 Methods

- 62 Synthetic sequences and clinical samples
- 63 An overview of the validation panels and study design is shown in **Figure 1**.

64 In order to mimic the complexity of clinical samples while reducing the number of additional viral 65 sequences, enabling sensitivity and specificity analyses, a panel was prepared of synthetic viral sequences (10⁰ - 10⁷ copies/ml) spiked in human cell free DNA (cf DNA) background sequences (Twist 66 Bioscience, San Francisco, USA). Synthetic viral sequences covered >99.9% of the viral genomes of 67 68 SARS-CoV-2, influenza A virus (Inf A), measles, enterovirus D68, and bocavirus and were mixed with 69 several proportions of human cfDNA (90-99.999% of weight, corresponding with proportions of up to 10-0.001%³¹ of viral nucleotides in a clinical sample^{12,32,33}). Concentrations of viral sequences were 70 71 determined by digital droplet PCR in triplicate (BioRad QX200). A total of 25 of synthetic mixtures were 72 included (see Suppl. Table 1).

Clinical EDTA plasma samples (n=8), previously submitted to the Clinical Microbiological Laboratory
 for routine diagnostic testing and tested positive by qPCR^{21,34} for adenovirus (ADV), Epstein-Barr virus
 (EBV) and Hepatitis B virus (HBV), were included in the comparison. Viral loads ranged from 500 to
 50,000 International Units (IU)/mI.

In addition, a dilution of ATCC Virome Virus Mix (MSA-2008[™], ATCC, Manassas, USA) of cultivated
adenovirus type F (ADV), cytomegalovirus (CMV), respiratory syncytial virus (RSV), influenza B virus,
reovirus 3, and zika virus was included.

80

81 Ethical approval

This study was approved by the medical ethics review committee Leiden/The Hague/Delft (CME number B20.002, 2020/2022).

84

85 Nucleic acids extraction

Clinical samples and the ATCC whole virus mixture were subjected to extraction of total nucleic acids
(NA) using the MagNAPure 96 DNA and Viral NA Small volume extraction kit (Roche, Basel,
Switzerland) as described previously²¹.

90 Viral metagenomic next-generation sequencing (mNGS)

91 Twist Comprehensive Viral Research Panel workflow

92 Sample preparation was performed using the Comprehensive Viral Research Panel workflow (Twist 93 Bioscience Corp.) according to the manufacturer's instructions. In short, 5 μ l of NA was used as input 94 for cDNA synthesis (Protoscript, New England Biolabs, Inc) followed by purification using magnetic beads, enzymatic fragmentation for 15 minutes at 30 °C, end repair and dA-tailing (Twist EF Library 95 96 Prep 2.0, Twist Bioscience Corp.). Next, unique molecular identifier (UMI) adapters with unique dual 97 barcodes (Twist UMI Adapter System, Twist Bioscience Corp.) were ligated to the fragments and 98 amplified using PCR (12 cycles). Amplified libraries were pooled per 8 samples and library pools were 99 used for hybridization with the Twist Comprehensive Virus probe panel, consisting of ~1 million 120 100 bp probes targeting 15,488 different viral strains infecting human and animals. Hybridization was 101 performed for 16 hours of incubation followed by several wash steps. Captured fragments were 102 further amplified by a post-hybridization PCR (15 cycles). Finally, captured libraries were purified by a 103 bead clean up using AmpureXP, and quantity and fragment size were determined using Qubit (Thermo 104 Fisher, Waltham, MA, USA) and Fragment Analyser (Agilent, Santa Clara, CA, USA) respectively. 105 Libraries were clustered and approximately 1 million 150bp paired-end reads were generated per 106 sample, according to manufacturer's protocols (Illumina Inc.) at GenomeScan B.V. using the 107 NovaSeq6000.

108

109 SeqCap EZ HyperCap (ViroCap design, Roche)

110 The SegCap EZ HyperCap workflow (Roche, Madison, USA) was performed as validated and described 111 previously^{10,21,35}. Briefly, 5 ul of NA was used as direct input (without concentration step) for enzymatic 112 fragmentation and cDNA synthesis using the NEBNext Ultra II Directional RNA Library preparation kit V3.0 (New England Biolabs, Ipswich, MA, USA) for Illumina with several in-house adaptations to enable 113 simultaneous detection of both DNA and RNA in a single tube per sample^{12,32}. After purification, dual 114 115 barcodes (NEBNext Multiplex oligos for illumina 96 unique dual index primer pairs) were attached to 116 the fragments and amplified using PCR (21 cycles). Four barcoded samples including controls were pooled, COT (enriched for repetitive sequences) human DNA and HyperCap Universal Blocking Oligos 117 were added before purification, following incubation for >40 hours with the SeqCap EZ HyperCap v1 118 119 (ViroCap design, 2015¹⁴), a collection of approximately two million oligonucleotide probes (70–120 120 mers) targeting all known vertebrate viruses. A complete list of the viral taxa included can be found in the supplementary tables of the manuscript by Briese et al¹⁴. Captured fragments were further 121

amplified by a post-hybridization PCR (14 cycles). Finally, captured libraries were purified by bead
clean up using AmpureXP, and quantity and fragment sizes were determined using Qubit (Thermo
Fisher, Waltham, MA, USA) and Fragment Analyser (Agilent, Santa Clara, CA, USA), respectively.
Approximately 10 million 150 bp paired-end reads were sequenced per sample according to
manufacturer's protocols (Illumina Inc.) at GenomeScan B.V. using the NovaSeq6000.

127

128 Data analysis

129 Bioinformatic analysis

Image analysis, base calling, and quality check of sequence data were performed with the Illumina 130 131 data analysis pipelines RTA3.4.4 and bcl2fastg v2.20 (Illumina). Sequence data obtained using both probe capture metagenomics methods were analyzed using a previously validated^{10,21,36,37} 132 133 bioinformatics pipeline. After quality pre-processing and removal of human reads (by mapping them 134 the human reference GRCh38 to genome (https://www.ncbi.nlm.nih.gov/assembly/GCF_000001405.26/ Bowtie2³⁸ with version 2.3.4), 135 datasets were analyzed using Genome Detective³⁹ version 2.48 (accessed April - May 2023) as 136 described previously³⁶. Genome Detective includes *de novo* assembly and both nucleotide and amino 137 138 acid based classification in combination with a RefSeq / Swiss-Prot Uniref database by Genome Detective³⁹ 139

Read counts were normalized for total read count and genome size using the formula: reads per kilobase per million (RPKM) = (number of reads mapped to the virus genome Y * 10⁶) / (total number of reads * length of the genome in kb)³⁷. To enable analyses of the percentage of genome coverage per one million total reads, one million raw reads were randomly selected³² from the 10 million reads generated for the Roche protocol. The random selection from raw FASTQ files was performed with the seqtk tool (https://github.com/lh3/seqtk, version 1.3).

146

147 Performance metrics and statistical analyses

Sensitivity and specificity were calculated using the results from the synthetic viral sequences and the ATCC Virome Virus mix. Additional findings were considered false positives, and non-vertebrate viruses were excluded from analyses. Receiver Operating Characteristic (ROC) curves were generated by varying the number of sequence-read counts used as cut-off for defining a positive result, given a prerequisite of \geq 3 genome regions covered⁴⁰, and area under the curves (AUC) were calculated.

- 153 Spearman correlations of sequence read counts with viral load, as determined by qPCR and ddPCR,
- were analyzed.
- 155 Limits of detection for both methods were determined using 10-fold serial dilutions of synthetic viral
- 156 NA in human cfDNA background, and undiluted clinical samples. Reproducibility was determined by
- analyzing the coefficient of variance between runs.
- 158 Statistical analyses were performed using SPSS version 25 and 29. Statistics with P-values of 0.05 and
- 159 lower were considered significant.

161 Results

162 Analytic sensitivity, specificity, and ROC

Detection of synthetic viral sequences in human cfDNA background, and the Virome Virus Mix, using 163 164 the Twist Comprehensive Viral Research Panel and the SeqCap EZ HyperCap (ViroCap) workflow is 165 depicted in **Suppl. Table 1**. For both methods, sensitivity was 100% (23/23, cycle threshold, C_T, values 166 ranging from 20 to 32). Viral target read counts ranged from 334-872,042 reads per million (RPM) for 167 the Twist Comprehensive Viral Research workflow, and 2,171- 971,610 RPM for the SeqCap EZ 168 HyperCap workflow. Genome coverage ranged from 91.1-100% (median 99.8%), and 8.4-100% 169 (median 97.5%), for these respective methods. Sensitivity and specificity were calculated for different 170 thresholds for defining a positive result: i) sequence read counts and ii) genome coverage percentage, as depicted in Figure 2 and Table 1. For calculation of the percentage of the viral genomes covered, a 171 random selection of 1 million sequence reads per dataset were used. Figure 2 shows that both RPM 172 173 and genome coverage were distinctive parameters for defining a true positive result, with AUC of 174 99.8% for both methods when considering RPM as parameter, and ≥99.7% when considering genome 175 coverage as parameter. Sensitivity and specificity scores of ≥95% were accomplished for both methods 176 when 500 RPM was set as threshold, on top of a prerequisite of minimum of three distributed regions 177 of the genome being covered (**Table 1**). Similarly, when coverage was set at 10% of the genome, both methods reached sensitivity and specificity levels of 95% and higher. Increasing the threshold for 178 179 genome coverage resulted in decreased sensitivity for the SeqCap EZ HyperCap workflow, whereas it did not negatively affect the outcomes of the Twist Comprehensive Viral Research Panel workflow. 180

181

182 Correlation of viral load and sequence read counts

Viral loads as determined by ddPCR on synthetic viral sequences in human cfDNA background, and by qPCR on clinical plasma samples, were compared with sequence read counts normalized by total library size and genome size (**Figure 3**). Read counts were significantly correlated with viral loads, for both methods. Outliers were detected for samples with low viral loads, likely attributable to the stochastic effect around the limits of detection of PCR and the sequencing protocols.

188

189 Limits of detection

190 The limits of detection of both probe capture methods were analysed for several ssRNA, dsDNA, and 191 ssDNA viruses, and is shown in **Figure 4** and **Suppl. Table 1**. The limits of detection for the RNA viruses

tested were approximately 50 and 500 copies/mL for the Twist Comprehensive Viral Research Panel

193 workflow and the SeqCap EZ HyperCap workflow, respectively. For the DNA viruses tested, the LOD

194 was approximately 500 IU/ml for both methods, apart from the limit of detection of HBoV, which was

approximately 5,000 c/ml using the SeqCap EZ HyperCap workflow.

196

197 Reproducibility

Between-run variability as generated by both probe hybridization metagenomic workflows was studied by repeated testing of clinical samples and synthetic sequences in presence of human cfDNA background (Figure 5 and Suppl. Table 1). Normalized sequence read counts and genome coverage percentage were analysed. Differences in target virus RPKM between runs were relatively low, ranging from 0.0 to 4.7% coefficients of variance.

203

204 Effect of human background sequences

The qualitative and quantitative effects of increased proportion of human background sequences on the detection of viral target sequences was studied using synthetic viral sequences spiked in a varying amount of human cfDNA background sequences (90% versus 99.999%, **Suppl. Figure 1**). No qualitative negative effect was found when the human cfDNA background proportion was increased. Quantitative target virus read counts were reduced in a single sample in which non-human reads were accounted for the largest proportion of the read count. Overall, these data indicated effective capture of target sequences.

212

213 Application of determined thresholds to clinical samples

214 Optimal thresholds for defining a positive result, determined as described above (using synthetic viral 215 sequences and the Virome Virus mixture) were applied to the eight clinical plasma samples with known viral loads (Suppl. Table 1). All qPCR positive findings were positive by mNGS, for both 216 methods. Additional findings when applying a threshold of minimal 500 RPM in combination with 10% 217 218 coverage of at least three regions of the genome were: torque teno viruses, adeno-associated 219 dependoparvovirus A, and polyomaviruses. The additional findings were consistent for both methods, 220 except for Merkel cell polyomavirus which was detected using the SegCap EZ HyperCap workflow in 221 two samples, indicating environmental contamination. The internal control sequences used in our 222 laboratory, equine arteritis virus (EAV) and phocid herpes virus (PhHV, both with C_T-values of

- approximately 33) were not detected and not part of the design of the Twist method, in contrast to
- the Roche method.

226 Discussion

227 These data show analytical performances in ranges acceptable for clinical samples, for both probe 228 hybridization targeted metagenomic approaches. A combination of RPM and percentage of genome 229 coverage were optimal for defining a positive result, accompanied by sensitivity and specificity well 230 over 95% for both methods. Limits of detection were within ranges applicable to clinical settings: 50-231 500 c/ml for the Twist protocol when thresholds of 500 RPM and 10% were considered. While 232 untargeted methods are intrinsically affected by the amount of background human DNA present in (tissue) samples⁴¹, the results of this study show effective capturing in increasing proportions of 233 234 human cell free DNA without significantly affecting the read counts and the coverage of the virus 235 genome. This study provides the first one-to-one comparison of two pan-viral metagenomic probe 236 capture workflows.

237 A recent report has studied a smaller probe panel targeting 29 human respiratory pathogenic viruses in comparison to the VirCapSeq (Roche)⁴². The authors conclude that the Twist Respiratory Virus Panel 238 239 workflow was suited for detection of both respiratory co-infections and SARS-CoV-2 variants with 240 >90% tenfold genome coverage. The latter is in line with our current data: genome coverage was 241 generally 90-100% for samples ≥1,000 C/ml, for a range of RNA and DNA viruses. It must be noted that 242 the required pooling of samples prior to hybridization lead to lower amounts of total reads generated 243 for lower biomass samples. Though this potentially may result in underestimation of the performance, 244 in practice, the sensitivity was 100% despite lower total counts in some cases using the Twist 245 workflow. Another report was recently published on the use of the Twist Comprehensive Viral Research Panel aiming at detection of viruses involved in pediatric hepatitis cases of unknown origin, 246 while an association with AAV2 was hypothesised⁴³. In 17 cases, AAV2 was detected using targeted 247 sequencing, while in seven of these pediatric cases AAV2 was missed by untargeted metagenomic 248 249 sequencing, illustrating the significance of the use of enrichment by hybridization. With regard to cost-250 efficiency, a recent study compared PCR, sequence-independent single primer amplification (SISPA), 251 and the Twist Comprehensive Viral Research Panel for the detection of Japanese encephalitis⁴⁴. The 252 authors concluded that the PCR panels were not able to detect all genotypes, whereas broader surveillance of vector-borne pathogens would be more effective though costly⁴⁴. Hybridization 253 254 capture has been approved by the FDA for SARS-CoV-2 variant monitoring, illustrating the 255 acknowledged significance of this type of enrichment. The limit of detection of the SARS-CoV-2 specific hybridization method in their study was 800 copies/ml⁴⁵, in line with our current and previous^{10,46} 256 findings when using the broader panel. Even using the panel designed in 2015¹⁴ resulted in excellent 257 genome coverage of SARS-CoV-2 due to sequence homology with animal coronaviruses and the 258 259 variability in the probe design allowing for sequence mismatches¹⁰.

260 This study has several limitations. The synthetic sequences spiked in cell free human DNA did not 261 contain other background nucleic acids such as bacterial and human RNA, though the latter proportion is generally low (<5%⁴⁷ dependent on the sample type). Furthermore, though ssRNA, dsDNA, and 262 ssDNA viruses were analyzed, detection and LOD results cannot be directly extrapolated to every 263 264 single virus. These parameters may vary to some extent for different viruses, particularly those not 265 included in the synthetic controls (manufactured by Twist). This was also exemplified by the lack of 266 detection of EAV and PhHV using the Twist Comprehensive Viral Research panel. Though these viruses 267 are not considered human pathogens, this illustrates the presence of certain restrictions with regard 268 to the animal viruses included in the panel. Further analyses of the lists of viruses delivered by the 269 probe designers showed that all pathogens on the WHO list of diseases with pandemic potential 270 (https://www.who.int/news/item/21-11-2022-who-to-identify-pathogens-that-could-cause-future-

271 <u>outbreaks-and-pandemics</u>) are present, in both probe panels.

272 To summarize, this study provides data supporting further steps towards widespread introduction of

viral metagenomics for pathogen detection in clinical settings. In addition, it provides guidance for

274 integration of probe hybridization methods in surveillance to track pathogens of pandemic potential

- in low biomass samples such as wastewater⁴⁸ and wild life swabs⁴⁹.
- 276

277 Author's contribution

- 278 Conceptualization: JJCV. Software: IS, Investigation; KM, AB. Methodology; KM, ECJC, JJCV. Software;
- 279 IS. Formal analysis: KM, IS. Supervision; ECC, AB, SAB, JJCV. Visualization: KM, JJCV. Roles/Writing -

280 original draft; KM, JJCV. Writing - review & editing: all authors.

281

282 Declaration of potential competing interest

DM and AB are employees of GenomeScan B.V. and provided the sequencing service. They were not
 involved in bioinformatic/statistical data analysis, nor interpretation of results.

285

286 Funding

This study was partially funded by Corona accelerated R&D in Europe (CARE Innovative MedicinesInitiative, IMI).

Table 1. Sensitivity and specificity resulting from varying thresholds based on a, sequence read counts and b, genome coverage percentage using a random selection of 1 million sequence reads per dataset, for the capture probe based metagenomic workflows SeqCap EZ HyperCap (Roche) and Twist Comprehensive Viral Research Panel workflow. Corresponding ROCs are shown in Fig. 2. RPM; read counts per million, LOD; limit of detection. For all tables, a minimum of three distributed regions of the genome covered was set as primary parameter for defining detection.

296 **a**

Thresholds based on read counts					
	50 RPM	500 RPM	5,000 RPM	50,000 RPM	
Twist Comprehensive Viral Research					
Sensitivity	1.000	0.957	0.870	0.739	
Specificity	0.960	0.979	0.995	1.000	
Corresponding	RNA: 10 ¹	RNA: 10 ¹	RNA: 10 ¹	RNA: 10 ²⁻⁴	
LOD (c/ml)*	DNA: 10 ²	DNA: 10 ²⁻³	DNA: 10 ²⁻³	DNA: 10 ⁴	
SeqCap EZ HyperCap workflow (Roche)					
Sensitivity	1.000	1.000	0.913	0.739	
Specificity	0.976	0.984	0.992	0.997	
Corresponding	RNA viruses: 10 ²	RNA: 10 ²	RNA: 10 ²	RNA: 10 ²⁻⁴	
LOD (c/ml)*	DNA viruses: 10 ²⁻³	DNA: 10 ²⁻³	DNA: 10 ²⁻⁴	DNA: 10 ^{4->}	

297

b

Thresholds based on genome coverage					
	5% coverage	10% coverage	20% coverage	90% coverage	
Twist Comprehensive Viral Research					
Sensitivity	1.000	1.000	1.000	0.957	
Specificity	0.950	0.968	0.987	1.000	
Corresponding LOD (c/ml)*	RNA viruses: 10 ¹ DNA viruses: 10 ²	RNA: 10 ¹⁻² DNA: 10 ²	RNA: 10 ² DNA: 10 ²	RNA: 10 ³ DNA: 10 ³ -10 ⁴	
SeqCap EZ HyperCap workflow (Roche)					
Sensitivity	1.000	0.957	0.870	0.696	
Specificity	0.973	0.981	0.995	0.997	
Corresponding LOD (c/ml)*	RNA: 10 ² DNA: 10 ²⁻³	RNA: 10 ³ -10 ⁴ DNA: 10 ²⁻³	RNA: 10 ³ -10 ⁴ DNA: 10 ²⁻⁶	RNA: 10 ⁴ DNA: 10 ^{3->4}	

298 *Based on LOD of Inf A, SARS-CoV-2, EBV, HBV, and bocavirus. Inf A; influenza A virus, EBV, Epstein-

299 Barr virus, HBV, hepatitis B virus.

300 301	Refere	nces
302 303 304	1	Gauthier, N. P. G., Chorlton, S. D., Krajden, M. & Manges, A. R. Agnostic Sequencing for Detection of Viral Pathogens. <i>Clin Microbiol Rev</i> 36 , e0011922 (2023). https://doi.org/10.1128/cmr.00119-22
305 306	2	Chiu, C. Y. & Miller, S. A. Clinical metagenomics. <i>Nat Rev Genet</i> 20 , 341-355 (2019). https://doi.org:10.1038/s41576-019-0113-7
307 308 200	3	Deng, X. <i>et al.</i> Metagenomic sequencing with spiked primer enrichment for viral diagnostics and genomic surveillance. <i>Nat Microbiol</i> 5 , 443-454 (2020). <u>https://doi.org:10.1038/s41564-</u> 010.0627.0
309 310	4	Wilson, M. R. et al. Clinical Metagenomic Sequencing for Diagnosis of Meningitis and
311	_	Encephalitis. <i>N Engl J Med</i> 380 , 2327-2340 (2019). <u>https://doi.org:10.1056/NEJMoa1803396</u>
312 313	5	Carbo, E. C. <i>et al.</i> Viral metagenomic sequencing in the diagnosis of meningoencephalitis: a review of technical advances and diagnostic yield. <i>Expert Rev Mol Diagn</i> 21 , 1139-1146 (2021).
314		https://doi.org:10.1080/14/3/159.2021.1985467
315 316	6	Carr, V. R. & Chaguza, C. Metagenomics for surveillance of respiratory pathogens. <i>Nat Rev</i> <i>Microbiol</i> 19 , 285 (2021). <u>https://doi.org:10.1038/s41579-021-00541-8</u>
317 318	/	Kafetzopoulou, L. E. <i>et al.</i> Metagenomic sequencing at the epicenter of the Nigeria 2018 Lassa fever outbreak. <i>Science</i> 363 , 74-77 (2019). <u>https://doi.org:10.1126/science.aau9343</u>
319 320	8	Holmes, E. C. COVID-19-lessons for zoonotic disease. <i>Science</i> 375 , 1114-1115 (2022). https://doi.org:10.1126/science.abn2222
321	9	Morfopoulou, S. et al. Genomic investigations of unexplained acute hepatitis in children.
322		Nature 617, 564-573 (2023). <u>https://doi.org:10.1038/s41586-023-06003-w</u>
323 324	10	Carbo, E. C. <i>et al.</i> Coronavirus discovery by metagenomic sequencing: a tool for pandemic preparedness. <i>J Clin Virol</i> 131 , 104594 (2020), https://doi.org/10.1016/j.jcv.2020.104594
325	11	Lopez-Labrador, F. X. <i>et al.</i> Recommendations for the introduction of metagenomic high-
326		throughput sequencing in clinical virology, part I: Wet lab procedure. J Clin Virol 134, 104691
327		(2021). https://doi.org:10.1016/j.jcv.2020.104691
328	12	van Rijn, A. L. et al. The respiratory virome and exacerbations in patients with chronic
329		obstructive pulmonary disease. PLoS One 14, e0223952 (2019).
330		https://doi.org:10.1371/journal.pone.0223952
331	13	Metsky, H. C. et al. Capturing sequence diversity in metagenomes with comprehensive and
332		scalable probe design. Nat Biotechnol 37, 160-168 (2019). https://doi.org:10.1038/s41587-
333		<u>018-0006-x</u>
334	14	Briese, T. et al. Virome Capture Sequencing Enables Sensitive Viral Diagnosis and
335		Comprehensive Virome Analysis. <i>mBio</i> 6 , e01491-01415 (2015).
336		https://doi.org:10.1128/mBio.01491-15
337	15	Wylie, T. N., Wylie, K. M., Herter, B. N. & Storch, G. A. Enhanced virome sequencing using
338		targeted sequence capture. Genome Res 25, 1910-1920 (2015).
339		https://doi.org:10.1101/gr.191049.115
340	16	Kuchinski, K. S. et al. Targeted genomic sequencing with probe capture for discovery and
341		surveillance of coronaviruses in bats. <i>Elife</i> 11 (2022). <u>https://doi.org:10.7554/eLife.79777</u>
342 343	17	Yamaguchi, J. et al. Universal Target Capture of HIV Sequences From NGS Libraries. Front Microbiol 9, 2150 (2018). https://doi.org:10.3389/fmicb.2018.02150
344	18	Wang, H. <i>et al.</i> Multiple-probe-assisted DNA capture and amplification for high-throughput
345		African swine fever virus detection. Appl Microbiol Biotechnol 107 , 797-805 (2023).
346		https://doi.org:10.1007/s00253-022-12334-x
347	19	Doddapaneni, H. et al. Oligonucleotide capture sequencing of the SARS-CoV-2 genome and
348		subgenomic fragments from COVID-19 individuals. PLoS One 16, e0244468 (2021).
349		https://doi.org:10.1371/journal.pone.0244468

medRxiv preprint doi: https://doi.org/10.1101/2023.08.23.23294459; this version posted August 24, 2023. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in

perpetuity. It is made available under a CC-BY-ND 4.0 International license .

350 20 Lythgoe, K. A. et al. SARS-CoV-2 within-host diversity and transmission. Science 372 (2021). 351 https://doi.org:10.1126/science.abg0821 352 21 Carbo, E. C. et al. Improved diagnosis of viral encephalitis in adult and pediatric hematological 353 patients using viral metagenomics. J Clin Virol 130, 104566 (2020). 354 https://doi.org:10.1016/j.jcv.2020.104566 355 22 Schuele, L. et al. Assessment of Viral Targeted Sequence Capture Using Nanopore Sequencing Directly from Clinical Samples. Viruses 12 (2020). https://doi.org:10.3390/v12121358 356 Wylie, K. M. et al. Detection of Viruses in Clinical Samples by Use of Metagenomic Sequencing 357 23 358 Targeted Capture. Clin Microbiol 56 (2018). and Sequence J https://doi.org:10.1128/JCM.01123-18 359 360 24 Jansen, S. A. et al. Broad Virus Detection and Variant Discovery in Fecal Samples of 361 Hematopoietic Transplant Recipients Using Targeted Sequence Capture Metagenomics. Front 362 Microbiol 11, 560179 (2020). https://doi.org:10.3389/fmicb.2020.560179 363 25 Stout, M. J., Brar, A. K., Herter, B. N., Rankin, A. & Wylie, K. M. The plasma virome in 364 longitudinal samples from pregnant patients. Front Cell Infect Microbiol 13, 1061230 (2023). 365 https://doi.org:10.3389/fcimb.2023.1061230 366 26 Garand, M. et al. Virome Analysis and Association of Positive Coxsackievirus B Serology during 367 Congenital Heart *Microorganisms* Pregnancy with Disease. 11 (2023). 368 https://doi.org:10.3390/microorganisms11020262 369 27 Flerlage, T. et al. Single cell transcriptomics identifies distinct profiles in pediatric acute 370 respiratory distress syndrome. Nat Commun 14, 3870 (2023).https://doi.org:10.1038/s41467-023-39593-0 371 372 28 Cassidy, H. et al. Exploring a prolonged enterovirus C104 infection in a severely ill patient using nanopore sequencing. Virus Evol 8, veab109 (2022). https://doi.org:10.1093/ve/veab109 373 374 29 Esnault, G. et al. Assessment of Rapid MinION Nanopore DNA Virus Meta-Genomics Using 375 Calves Experimentally Infected with Bovine Herpes Virus-1. Viruses 14 (2022). 376 https://doi.org:10.3390/v14091859 377 30 Zhang, C. et al. Characterization of the Eukaryotic Virome of Mice from Different Sources. 378 Microorganisms 9 (2021). https://doi.org:10.3390/microorganisms9102064 379 31 Junier, T. et al. Viral Metagenomics in the Clinical Realm: Lessons Learned from a Swiss-Wide 380 Ring Trial. Genes (Basel) 10 (2019). https://doi.org:10.3390/genes10090655 381 van Boheemen, S. et al. Retrospective Validation of a Metagenomic Sequencing Protocol for 32 Combined Detection of RNA and DNA Viruses Using Respiratory Samples from Pediatric 382 383 Patients. J Mol Diagn 22, 196-207 (2020). https://doi.org:10.1016/j.jmoldx.2019.10.007 384 33 Morfopoulou, S. et al. Deep sequencing reveals persistence of cell-associated mumps vaccine (2017). 385 virus in chronic encephalitis. Acta Neuropathol 133, 139-147 386 https://doi.org:10.1007/s00401-016-1629-y 387 Carbo, E. C. et al. Longitudinal Monitoring of DNA Viral Loads in Transplant Patients Using 34 388 Quantitative Metagenomic Next-Generation Sequencing. Pathogens 11 (2022).389 https://doi.org:10.3390/pathogens11020236 390 35 Reyes, A. et al. Viral metagenomic sequencing in a cohort of international travellers returning 391 with febrile illness. J Clin Virol 143, 104940 (2021). https://doi.org:10.1016/j.jcv.2021.104940 Carbo, E. C. et al. Performance of Five Metagenomic Classifiers for Virus Pathogen Detection 392 36 393 Using Respiratory Samples from а Clinical Cohort. Pathogens 11 (2022). 394 https://doi.org:10.3390/pathogens11030340 de Vries, J. J. C. et al. Benchmark of thirteen bioinformatic pipelines for metagenomic virus 395 37 396 diagnostics using datasets from clinical samples. J Clin Virol 141, 104908 (2021). 397 https://doi.org:10.1016/j.jcv.2021.104908 Langmead, B. & Salzberg, S. L. Fast gapped-read alignment with Bowtie 2. Nat Methods 9, 357-398 38 399 359 (2012). https://doi.org:10.1038/nmeth.1923

- 400 39 Vilsker, M. et al. Genome Detective: an automated system for virus identification from high-401 throughput sequencing data. **Bioinformatics** 35, 871-873 (2019). 402 https://doi.org:10.1093/bioinformatics/bty695
- de Vries, J. J. C. et al. Recommendations for the introduction of metagenomic next-generation 403 40 404 sequencing in clinical virology, part II: bioinformatic analysis and reporting. J Clin Virol 138, 405 104812 (2021). https://doi.org:10.1016/j.jcv.2021.104812
- Lewandowska, D. W. et al. Optimization and validation of sample preparation for 406 41 metagenomic sequencing of viruses in clinical samples. Microbiome 5, 94 (2017). 407 408 https://doi.org:10.1186/s40168-017-0317-z
- 409 Kim, K. W. et al. Respiratory viral co-infections among SARS-CoV-2 cases confirmed by virome 42 410 capture sequencing. Sci Rep 11, 3934 (2021). https://doi.org:10.1038/s41598-021-83642-x
- 411 43 Servellita, V. et al. Adeno-associated virus type 2 in US children with acute severe hepatitis. Nature 617, 574-580 (2023). https://doi.org:10.1038/s41586-023-05949-1 412
- 413 Crispell, G. et al. Method comparison for Japanese encephalitis virus detection in samples 44 414 collected from the Indo-Pacific region. Front Public Health 10, 1051754 (2022). 415 https://doi.org:10.3389/fpubh.2022.1051754
- Nagy-Szakal, D. et al. Targeted Hybridization Capture of SARS-CoV-2 and Metagenomics 416 45 417 Enables Genetic Variant Discovery and Nasal Microbiome Insights. Microbiol Spectr 9, 418 e0019721 (2021). https://doi.org:10.1128/Spectrum.00197-21
- 419 Carbo, E. C. et al. A comparison of five Illumina, Ion Torrent, and nanopore sequencing 46 technology-based approaches for whole genome sequencing of SARS-CoV-2. Eur J Clin 420 421 Microbiol Infect Dis 42, 701-713 (2023). https://doi.org:10.1007/s10096-023-04590-0
- 422 47 Wu, J. et al. Ribogenomics: the science and knowledge of RNA. Genomics Proteomics 423 Bioinformatics 12, 57-63 (2014). https://doi.org:10.1016/j.gpb.2014.04.002
- 424 48 Clark, J. R. et al. Wastewater pandemic preparedness: Toward an end-to-end pathogen 425 monitoring Public Health 11, 1137881 program. Front (2023).426 https://doi.org:10.3389/fpubh.2023.1137881
- 427 49 Lwande, O. W. et al. Alphacoronavirus in a Daubenton's Myotis Bat (Myotis daubentonii) in 428 Sweden. Viruses 14 (2022). https://doi.org:10.3390/v14030556

Study design and workflow



Fig. 1. Workflows of the capture probe-based targeted metagenomic protocols compared in this study, Twist Comprehensive Viral Research, and the SeqCap EZ HyperCap (ViroCap, Roche) and, both in combination with identical bioinformatic analyses pipeline. Created using BioRender.





Fig. 2. Receiver operating characteristic curves (ROC) for prediction of detection of viral sequences using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research, and SeqCap EZ HyperCap (Roche). The validation panel consisted of synthetic viral sequences spiked in a background of human cell-free DNA (90-99.999%) and diluted ATCC Virome virus mix standard (copies/mL ranging from 10⁴ to 10⁷). **a**, ROC based on sequence read counts per million (RPM), and **b**, percentage of genome coverage, using a random selection of 1 million sequence reads per dataset. For all curves a minimum of three distributed regions of the genome covered was set as primary parameter for defining detection.





Fig. 3. Correlation graph depicting linearity between the viral load (VL, log₁₀ IU and C/ml, horizontally) and the log₁₀ read counts per million per kb genome (RKPM) as generated using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research and SeqCap EZ HyperCap (Roche). Included are detections by both methods from synthetic viral sequences spiked in a background of human cell-free DNA (90/99%), dilution series (see Fig. 4), and clinical samples.



Fig. 4. Limit of detection of viral sequences using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research (depicted in the left upper corner, 'C'), and SeqCap EZ HyperCap (Roche, depicted in the right lower corner, 'H'). Read counts per million per kb genome (RPKM) are shown for different viral loads (C/mI). The samples consisted of synthetic viral sequences spiked in a background of human cell-free DNA (90-99,999%) (Inf A, SARS-CoV-2, HBoV), and clinical EDTA plasma samples (ADV, EBV, HBV). Created using BioRender.



Fig. 5. Reproducibility of read counts and genome coverage percentages. Between-run variability in RPKM (left axis) and genome coverage percentage (right axis) as generated using the virus capture probe based metagenomic workflows Twist Comprehensive Viral Research and SeqCap EZ HyperCap (Roche). Percentage of genome coverage was based on a random selection of 1 million sequence reads per dataset. Coefficients of variance in RPKM ranged from 0.0-4.7% (see Suppl. Table 1). Created using BioRender.